NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer

HER2+ breast cancer (BC) is characterized by rapid growth, early recurrence, early metastasis, and chemoresistance. Trastuzumab is the most effective treatment for HER2+ BC and effectively reduces the risk of recurrence and death of patients. Resistance to trastuzumab results in cancer recurrence an...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Lili, Ren, Liangliang, Chen, Han, Pan, Jinyuan, Zhang, Zhuojun, Kuang, Xiangqin, Chen, Xuhong, Bao, Wenhao, Lin, Chun, Zhou, Zhongqiu, Huang, Danping, Yang, Jianan, Huang, Hongbiao, Wang, Lan, Hou, Ning, Song, Libing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368860/
https://www.ncbi.nlm.nih.gov/pubmed/32683421
http://dx.doi.org/10.1038/s41419-020-02753-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368860/
https://www.ncbi.nlm.nih.gov/pubmed/32683421
http://dx.doi.org/10.1038/s41419-020-02753-x

Ejemplares similares